Menlo Park, Calif., January 30, 2014 - Geron Corporation (Nasdaq: GERN) today announced the pricing of its previously announced underwritten public offering of 22,500,000 shares of its common stock, offered at a price to the public of $4.00 per share. The gross proceeds to Geron from this underwritten public offering are expected to be approximately $90 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron. The offering is expected to close on or about February 4, 2014, subject to the satisfaction of customary closing conditions. Geron has also granted the underwriters an option to purchase up to an aggregate of 3,375,000 additional shares of its common stock offered in the public offering, exercisable for 30 days. All of the shares in the offering are to be sold by Geron.

Geron intends to use the net proceeds from this public offering to fund research and development, including the company's planned Phase 2 clinical trial of imetelstat in myelofibrosis, and for working capital and general corporate purposes.

BofA Merrill Lynch acted as sole book-running manager; Stifel acted as lead manager and Lazard Capital Markets LLC, Piper Jaffray & Co. and MLV & Co. acted as co-managers for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement may also be obtained from the offices of BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email at dg.prospectus_requests@baml.com.

About Geron

Geron is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Forward-Looking Information is Subject to Risk and Uncertainty

Investors are cautioned that statements in this press release regarding the anticipated gross proceeds from the offering and completion and timing of the public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: market and other conditions; whether there are any new significant adverse events reported related to imetelstat; the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Geron will be able to complete the public offering on the anticipated terms, or at all. Geron will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force Geron to delay, reduce or eliminate its imetelstat clinical development program. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on other potential factors that could affect Geron's results and other risks and uncertainties can be found under the heading "Risk Factors" in Geron's preliminary prospectus supplement related to the public offering filed with the Securities and Exchange Commission on January 29, 2014 available on the SEC's web site at www.sec.gov. Geron expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com


HUG#1758087


distributed by